Om Manchanda, CEO of Dr Lal Pathlabs, spoke to CNBC-TV18 about the company's business plans and shared outlook for FY20.
“We are the single largest player in the industry but our market share is still very low; it’s highly underpenetrated, underserved market,” said Manchanda.
About the expansion plans, he said, “The geographical expansion that we are doing is helping us grow both on volumes as well as on value.”
“After Delhi NCR our focus in the last few years has been east and rest of India and we have reasonably good success in rest of India in the last few quarters,” he added.
Talking about the growth, Manchanda said, “I won’t focus on quarterly fluctuations and we want to stay away from giving yearly guidance as well, but growth can certainly be higher because the potential is so much and our presence is lopsided towards north and east. There is so much to do in this country.”
“Being the largest diagnostic player we bring a lot of quality, affordability on the table. We bring the service level which no one else can provide and we can play a much bigger role of achieving scale pan-India,” he added.